Overview
Peripheral T-cell lymphoma (PTCL) is a rare cancer of the lymphatic system caused by T-cells, a type of white blood cells. It is not related to Hodgkin lymphoma, which is a cancer of lymphocytes (B-cells). PTCL can be classified into many subtypes and has different prognoses depending on type, staging, and other features. Its symptoms may include feeling tired, enlarged lymph nodes, enlarged spleen, fever, and weight loss. Treatment usually involves chemotherapy and radiation therapy. With the development of new therapies, early detection and better management, the prognosis of PTCL is improving.
Research published in this journal
4 peer-reviewed articles, ranked by relevance. Each links to its DOI.
How this research is being cited
The 4 articles above have been cited 11 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2026 · Biomolecules
-
2023 · Expert Opinion on Drug Discovery
-
2022 · Expert Opinion on Drug Discovery
-
2022 · ecancermedicalscience
-
J. Adomako et al. · 2022 · ecancermedicalscience
-
I. V. Chernikov et al. · 2021 · Russian journal of bioorganic chemistry
-
2021 · Russian Journal of Bioorganic Chemistry
-
I. Akpan et al. · 2021 ·
A sample of recent works citing this journal's research on Peripheral T-cell Lymphoma, linking to each citing work.